Aligos Therapeutics, Inc. Depreciation
Aligos Therapeutics, Inc. (ALGS) reported Depreciation of $300.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-06
- Aligos Therapeutics, Inc. depreciation for the quarter ending 2026-06-30 was $300.00K, a 0.00% change year-over-year.
- Aligos Therapeutics, Inc. depreciation for the quarter ending 2026-03-31 was $346.00K, a 78.35% increase year-over-year.
- Aligos Therapeutics, Inc. depreciation for the quarter ending 2025-12-31 was $257.00K, a 6.64% increase year-over-year.
- Aligos Therapeutics, Inc. depreciation for the quarter ending 2025-09-30 was $200.00K, a 33.33% decline year-over-year.
- Aligos Therapeutics, Inc. depreciation for fiscal 2025 was $930.00K, a 9.44% decline from fiscal 2024.
- Aligos Therapeutics, Inc. depreciation for fiscal 2024 was $1.03M, a 34.12% decline from fiscal 2023.
- Aligos Therapeutics, Inc. depreciation for fiscal 2023 was $1.56M, a 32.39% decline from fiscal 2022.
- Aligos Therapeutics, Inc. depreciation for fiscal 2022 was $2.31M, a 23.62% decline from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 3 month as first filed | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $300.00K 10-Q · filed 2026-08-06 | $601.00K 10-Q · filed 2026-08-06 | $903.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.10M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $346.00K 10-Q · filed 2026-05-07 | $603.00K derived: sum of 2 quarters · filed 2026-05-07 | $803.00K derived: sum of 3 quarters · filed 2026-05-07 | $1.10M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $257.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $457.00K derived: sum of 2 quarters · filed 2026-03-05 | $757.00K derived: sum of 3 quarters · filed 2026-08-06 | $930.00K 10-K · filed 2026-03-05 | |
| 2025-09-30 | $200.00K 10-Q · filed 2025-11-06 | $500.00K derived: sum of 2 quarters · filed 2026-08-06 | $673.00K 10-Q · filed 2025-11-06 | $935.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $300.00K 10-Q · filed 2026-08-06 | $453.00K 10-Q · filed 2026-08-06 | $735.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.03M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $194.00K 10-Q · filed 2026-05-07 | $435.00K derived: sum of 2 quarters · filed 2026-05-07 | $735.00K derived: sum of 3 quarters · filed 2026-05-07 | $1.03M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $241.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $541.00K derived: sum of 2 quarters · filed 2026-03-05 | $841.00K derived: sum of 3 quarters · filed 2026-03-05 | $1.03M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $300.00K 10-Q · filed 2025-11-06 | $600.00K derived: sum of 2 quarters · filed 2025-11-06 | $786.00K 10-Q · filed 2025-11-06 | $1.28M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $300.00K 10-Q · filed 2025-08-06 | $538.00K 10-Q · filed 2025-08-06 | $976.00K derived: sum of 3 quarters · filed 2025-08-06 | $1.28M derived: sum of 4 quarters · filed 2025-08-06 | |
| 2024-03-31 | $282.00K 10-Q · filed 2025-05-06 | $676.00K derived: sum of 2 quarters · filed 2025-05-06 | $976.00K derived: sum of 3 quarters · filed 2025-05-06 | $1.38M derived: sum of 4 quarters · filed 2025-05-06 | |
| 2023-12-31 | $394.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $694.00K derived: sum of 2 quarters · filed 2025-03-10 | $1.09M derived: sum of 3 quarters · filed 2025-03-10 | $1.56M 10-K · filed 2025-03-10 | |
| 2023-09-30 | $300.00K 10-Q · filed 2024-11-06 | $700.00K derived: sum of 2 quarters · filed 2024-11-06 | $1.17M 10-Q · filed 2024-11-06 | $1.68M derived: sum of 4 quarters · filed 2024-11-06 | |
| 2023-06-30 | $400.00K 10-Q · filed 2024-08-06 | $858.00K 10-Q · filed 2024-08-06 | $1.38M derived: sum of 3 quarters · filed 2024-08-06 | $1.88M derived: sum of 4 quarters · filed 2024-08-06 | |
| 2023-03-31 | $454.00K 10-Q · filed 2024-05-07 | $976.00K derived: sum of 2 quarters · filed 2024-05-07 | $1.48M derived: sum of 3 quarters · filed 2024-05-07 | $2.08M derived: sum of 4 quarters · filed 2024-05-07 | |
| 2022-12-31 | $522.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $1.02M derived: sum of 2 quarters · filed 2024-03-12 | $1.62M derived: sum of 3 quarters · filed 2024-03-12 | $2.31M 10-K · filed 2024-03-12 | |
| 2022-09-30 | $500.00K 10-Q · filed 2023-11-02 | $1.10M derived: sum of 2 quarters · filed 2023-11-02 | $1.78M 10-Q · filed 2023-11-02 | $2.50M derived: sum of 4 quarters · filed 2023-11-02 | |
| 2022-06-30 | $600.00K 10-Q · filed 2023-08-03 | $1.25M 10-Q · filed 2023-08-03 | $2.00M derived: sum of 3 quarters · filed 2023-08-03 | $2.80M derived: sum of 4 quarters · filed 2023-08-03 | |
| 2022-03-31 | $676.00K 10-Q · filed 2023-05-04 | $1.40M derived: sum of 2 quarters · filed 2023-05-04 | $2.20M derived: sum of 3 quarters · filed 2023-05-04 | $3.00M derived: sum of 4 quarters · filed 2023-05-04 | |
| 2021-12-31 | $728.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $1.53M derived: sum of 2 quarters · filed 2023-03-09 | $2.33M derived: sum of 3 quarters · filed 2023-03-09 | $3.02M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $800.00K 10-Q · filed 2022-11-02 | $765.00K 10-Q · filed 2021-11-04 | $1.60M derived: sum of 2 quarters · filed 2022-11-02 | $2.29M 10-Q · filed 2022-11-02 | $3.07M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $800.00K 10-Q · filed 2022-08-04 | $764.00K 10-Q · filed 2021-08-05 | $1.51M 10-Q · filed 2022-08-04 | $2.27M derived: sum of 3 quarters · filed 2022-08-04 | $2.98M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $741.00K 10-Q · filed 2022-05-04 | $1.47M derived: sum of 2 quarters · filed 2022-05-04 | $2.18M derived: sum of 3 quarters · filed 2022-05-04 | $2.86M derived: sum of 4 quarters · filed 2022-05-04 | |
| 2020-12-31 | $730.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $1.44M derived: sum of 2 quarters · filed 2022-03-10 | $2.12M derived: sum of 3 quarters · filed 2022-03-10 | $2.73M 10-K · filed 2022-03-10 | |
| 2020-09-30 | $708.00K 10-Q · filed 2021-11-04 | $1.39M derived: sum of 2 quarters · filed 2021-11-04 | $2.00M 10-Q · filed 2021-11-04 | $2.25M derived: sum of 4 quarters · filed 2021-11-04 | |
| 2020-06-30 | $680.00K 10-Q · filed 2021-08-05 | $1.29M 10-Q · filed 2021-08-05 | $1.54M derived: sum of 3 quarters · filed 2021-08-05 | $1.93M derived: sum of 4 quarters · filed 2021-08-05 | |
| 2020-03-31 | $331.00K 10-Q · filed 2021-05-10 | $859.00K derived: sum of 2 quarters · filed 2021-05-10 | $1.25M derived: sum of 3 quarters · filed 2021-05-10 | ||
| 2019-12-31 | $528.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $915.00K derived: sum of 2 quarters · filed 2021-03-23 | $1.40M 10-K · filed 2021-03-23 | ||
| 2019-09-30 | $387.00K 10-Q · filed 2020-11-25 | $868.00K 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |